Dr. Karin Hehenberger, MD, PhD is an accomplished medical and business expert in the biopharmaceutical industry with over 15 years of experience in leadership positions at top companies such as Johnson & Johnson and Eyetech Pharmaceuticals. Dr. Hehenberger's post-doctorate at the Joslin Diabetes Center, Harvard Medical School, and her time serving on the senior team at the JDRF showcases her dedication to diabetes research. She received her MD and PhD from the renowned Karolinska Institute in Stockholm, Sweden, where she still holds a position with the Department of Endocrinology and Surgery.

Notably, Dr. Hehenberger is also the co-founder and CEO of Lyfebulb, a company working to reduce the burden of chronic disease through empowering patient entrepreneurs and ambassadors. She has been a board member for various organizations, including the American Diabetes Association, Amal Therapeutics, and the Foundation at Alliance for Regenerative Medicine. Dr. Hehenberger has also held positions as a medical and scientific consultant at Helsinn Group and as a senior partner at SLS Venture.

Overall, Dr. Karin Hehenberger is an accomplished medical professional, dedicated diabetes researcher, and experienced business leader with an impressive history of success and impact in the biopharmaceutical industry.